09/30 Taiwan BIO Weekly
2025-09-30 |
| Taiwan BIO Weekly |
| HanchorBio raises NT$680mil to boost R&D 26 September, 2025 New drug development company HanchorBio (TW: 7827) announced that its first cash capital increase for 2025 has been successfully completed. A total of 10million new shares were issued at a premium of NT$68 per share, raising NT$680 million in full. The record date for the capital increase was September 25. The company stated that the funds raised will be used to strengthen operating capital and fully advance the clinical trials of its protein-based innovative drugs HCB101 and HCB301. Both drugs have broad-spectrum anti-cancer potential and aim to address unmet medical needs, with the goal of accelerating market entry to benefit more cancer patients. More... (in Chinese) |
| Targeting NT$50bil market, Everfortune.AI launches caregiving robot 26 September, 2025 Everfortune.AI (TW: 6841) unveiled its first generative AI caregiving robot prototype at its September 25 investor conference. The robot will undergo a three-month on-site proof-of-concept trial at China Medical University Hospital starting in October, with mass production planned for Q1 next year. The first-generation robot offers navigation, health education consultation, meal ordering, and remote ward round services, available via a leasing model with annual fees of NT$500,000-800,000. Orders have already begun, targeting a projected NT$50 billion market over five years under the Healthy Taiwan Plan. More... (in Chinese) |
| Tanvex BioPharma begins commercial-scale production in the US, first Taiwanese biosimilar to enter US market 25 September, 2025 Tanvex BioPharma (TW: 6541) has officially launched its biosimilar NYPOZI in the US market through its partner Cipla, becoming the first Taiwanese company to bring a biosimilar to the United States. Under a licensing and manufacturing agreement signed in June, Cipla handles marketing and sales while Tanvex BioPharma, as the registered manufacturer, manages commercial-scale production and supply. The company expects to generate revenue through product sales, royalties, milestone payments, and post-launch profit-sharing, while leveraging US-based manufacturing to expand CDMO business opportunities. More... (in Chinese) |
| 2025 Taipei Biotechnology Award winners announced 24 September, 2025 The Taipei Biotechnology Awards has celebrated its 22nd edition. The 2025 ceremony was held at the Han Lai Hotel Taipei, with Taipei Mayor Wayne Chiang presenting the honors. According to the organizers, 20 biotech companies and academic institutions stood out this year. The Gold Award in the Innovation category went to TST Biomedical Electronics, Health Ever Bio-Tech, and Hughes Biotechnology. The Gold Award for Interdisciplinary Excellence was given to China Medical University Hospital. No Gold Award was presented for the Go Global category, but the Silver Award went to BioGend Therapeutics. The special Taipei Biotech Star award was presented to AnnJi Pharmaceutical. More... (in Chinese) |
| Lotus Pharmaceuticals to acquire US Aiviqun, revenue and profit expected to double 24 September, 2025 Lotus Pharmaceuticals (TW: 1795) announced it will acquire US-based Alvogen US for US$658 million (around NT$20 billion). The deal, revealed in a press conference attended by Chairman Vilhelm Robert Wessman, GM Petar Antonov Vazharov, and SVP Bjartur Shen, is expected to double Lotus's revenue and profits. Post-merger, Lotus will become one of the top 20 global specialty pharmaceutical companies, with nearly 100 products and enhanced US commercial and FDA-compliant manufacturing capabilities. More... |
| EirGenix's EG1206A Phase III Clinical Trial receives FDA agreement for potential early termination 24 September, 2025 EirGenix (TW: 6589) announced that consultations with the US FDA and the European Medicines Agency (EMA) regarding its investigational product EG1206A's Phase III clinical trial received positive feedback. The company has decided to terminate the Phase III trial, potentially allowing the product to enter the market earlier. EG1206A, a pertuzumab biosimilar, is primarily intended for the treatment of early-stage and metastatic HER2-positive breast cancer. More... (in Chinese) |
| Radiopharmaceuticals company PET Pharm Biotech applies for Innovation Board listing 24 September, 2025 The Taiwan Stock Exchange announced that PET Pharm Biotech (TW: 7762), a nuclear medicine drug company, has submitted its application to list its shares on the Innovation Board. PET Pharm Biotech is the eighth company this year to apply for listing on the Innovation Board. PET Pharm Biotech's main products include PIC/S GMP sterile preparations and radiopharmaceuticals, and is also engaged in new drug development. More... (in Chinese) |
| Targeting a trillion-TWD biotech industry, Lai launches five strategies 24 September, 2025 President Lai Ching-te announced that Taiwan will implement five major strategies to boost biotech innovation and resilience. The plan includes leveraging the National Development Fund to invest billions in smart healthcare startups, expanding private-sector participation, and strengthening the national biotech ecosystem. Lai set a goal for the biotech industry to reach trillion-TWD scale. He noted that recent challenges, including the pandemic, the US Inflation Reduction Act, and new tariffs, make enhancing industry resilience urgent. More... (in Chinese) |
| TWi Biotechnology to enter peak licensing revenue period next year 24 September, 2025 TWi Biotechnology (TW: 6610) is set to benefit from updates to its drug pipeline, with its postpartum depression oral drug NORA520, which will release Phase II unblinding data in Q4. Its topical treatment for simplex epidermolysis bullosa (EBS), AC-203, is planned for a Phase II/III interim analysis in Q1 next year. The company stated that as these two new drugs start showing results, the company will enter a peak licensing revenue period next year. More... (in Chinese) |
| HuniLife Biotechnology's multiple myeloma drug administered to first patient in clinical trial 24 September, 2025 HuniLife Biotechnology announced that its investigational drug HuL001 was administered to the first multiple myeloma patient at Far Eastern Memorial Hospital. This marks the official start of the clinical trial and a key milestone in the development of HuL001, offering new hope for patients. Recently, HuniLife completed a board restructuring, appointing Wu Chung-hsiun, former CEO of the Development Center for Biotechnology, as chairman, and naming Gloria Huang, with a US accounting background, as CEO. Wu emphasized that HuL001 has the potential to become a new treatment option for relapsed or refractory multiple myeloma, and may even serve as an immunotherapy capable of shifting the current paradigm in cancer treatment. He expressed hope that positive future data will attract more international collaborations and licensing opportunities, advancing the drug’s development. More... (in Chinese) |
| REGiMMUNE targets listing in H1 next year 23 September, 2025 REGiMMUNE, Japan's first biotech aiming for a Taiwan stock market listing, reported that its GvHD immunomodulatory drug RGI-2001 has completed Phase IIb trials at seven top US medical centers, with Phase III expected next year. The Phase IIb results were published in the journal Blood. To support its OTC listing, REGiMMUNE plans a pre-OTC private placement to raise NT$300-360 million at NT$56 per share. Founded in 2006, the company's main shareholders are Daiwa Securities, JAIC, and SMBC Venture Capital, with domestic investors including BioPhoenix. More... (in Chinese) |
| Taiwan, Thailand ink deal to speed AI healthcare rollout 23 September, 2025 Taiwan and Thailand yesterday signed a memorandum of understanding (MOU) to cooperate on validating artificial intelligence (AI) medical models, aiming to accelerate the commercialization of smart healthcare technologies, Taiwan's Ministry of Health and Welfare said. More... (in Chinese) |
| UnicoCell to go public in October, operations focused on three key areas 23 September, 2025 In a recent announcement UnicoCell (TW: 6794) said that it is expected to list in October. Currently the company is focused on three core areas: stem cell drug development, exosome-derived stem cell secretions, and cell production technology services. The company's new therapies for knee osteoarthritis and chronic kidney disease aim to obtain temporary drug approval once regenerative medicine methods are implemented. More... (in Chinese) |
| Shine-On BioMedical promotes its technology platforms, targets early-stage licensing deals and plans listing on the Taipei Exchange next year 23 September, 2025 Shine-On BioMedical (TW: 6926) recently held an investor conference, and stated that it possesses two major technology platforms: tri-specific antibodies and exosome drug delivery systems. The company is targeting early-stage licensing deals and plans to formally list on the Taipei Exchange next year. Shine-On BioMedical also recently announced that it has signed a licensing agreement with Singapore's Esco Aster Pte. Ltd. for its patented exosome small-molecule drug loading technology covering Southeast Asia and the New Zealand-Australia region (excluding Taiwan). More... (in Chinese) |
| Highlights at BIO Asia-Taiwan 2025 23 September, 2025 At BIO Asia-Taiwan 2025, ITRI unveiled several groundbreaking technology innovations, demonstrating its strong capabilities in biomedical R&D. Highlights included next-generation long-acting vaccine adjuvants, novel therapies for cancer and eye diseases, and AI-driven platforms for diagnostics and data analysis. More... |
| Taiwan's Advanced Biomed launch next-gen platform for precision medicine and drug discovery 19 September, 2025 Advanced Biomed Inc. a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, announced the launch of its A+PerfusC system, a compact, all?in?one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. More... |
| Taiwan tech foundation expands to smart medical services 19 September, 2025 The ASUS Foundation announced Friday (Sept. 19) it has expanded its international volunteer program to include smart medical technology for the first time. The Taiwan-based technology foundation reached eight countries this year as part of efforts to bridge digital divides in underserved communities. The expansion marks a significant shift from purely educational technology initiatives to comprehensive healthcare support. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |